Publications by authors named "M Millward"
Introduction: Maximal heterozygosity on the human leukocyte antigen (HLA) loci has been found to be associated with improved survival and development of immune-related adverse events (irAEs) among NSCLC patients treated with immunotherapy. Here, we investigated the effect of germline HLA-I/-II on clinical outcomes among NSCLC patients treated with first-line pembrolizumab in combination with chemotherapy.
Method: We prospectively recruited patients with NSCLC who were commencing first-line pembrolizumab in combination with chemotherapy.
This single-arm phase II non-randomised trial (ACTRN12619001265167) evaluated trastuzumab emtansine in solid cancers with HER2 amplification or mutation detected by comprehensive genomic profiling. The primary objective was objective response (OR), while secondary objectives included the time to progression (TTP) on study to TTP on prior therapy ratio, progression-free survival (PFS) and overall survival (OS). The cohort included 16 tumours with HER2 mutations (group 1) and 16 with HER2 amplification (group 2).
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to assess the implementation of complex genomic sequencing (CGS) for advanced cancer patients, involving DNA testing and patient surveys to evaluate how CGS could influence their treatment.
- Out of the 199 patients tested, a significant number (63%) had findings that could impact their management, with 16% experiencing changes in therapy based on CGS results within six months.
- Patients generally felt satisfied with the CGS process, appreciating its potential benefits, although many overestimated the likelihood of their results affecting treatment; clinicians emphasized the importance of effective communication during the process.
Purpose: In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS). Here, we investigate progression-free survival (PFS) and OS after postrecurrence systemic therapy.
Patients And Methods: Patients 15 years or older with resected stage IIIB-C/IV melanoma were stratified by stage and tumor PD-L1 status and randomly assigned to receive nivolumab 3 mg/kg every 2 weeks, or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year or until disease recurrence, unacceptable toxicity, or withdrawal of consent.
Article Synopsis
- - Davoceticept (ALPN-202) is an experimental treatment designed to enhance immune response by targeting PD-L1 and CTLA-4, and its effectiveness was assessed in two studies: NEON-1 (monotherapy) and NEON-2 (in combination with pembrolizumab) on patients with advanced solid tumors.
- - In NEON-1, 58 participants received varying doses of davoceticept, and in NEON-2, 29 patients received davoceticept alongside pembrolizumab, with safety and efficacy monitored through adverse events and tumor response.
- - Results indicated that 67% of participants in NEON-1 and 62% in NEON-